āagman

Not investment advice. Data and computed figures, for information only.

Alembic Pharmaceuticals Ltd

NSE: APLLTD
₹792.65
+₹0.20 (+0.03%)
NSE · 15 Oct 2026, close
NSE
As of 31 Mar 2026
Market Cap
₹16,978 Cr
CMP
₹792.65
52-wk High / Low
₹998 / 636
P/E
22.8
P/B
3.0
Book Value
₹289.0
Div Yield
1.39%
ROCE
13.0%
ROE
13.4%
Face Value
₹2
D/E
0.25

Price−16.4% over 1Y

āagman read

Computed by āagman
Derived from 12 years and 13 quarters of filings. Not reported by the company.
As of 15 Oct 2026
How we compute these
Piotroski F-Score
6
/ 9
6 of 9 F-score tests passed
Graham Number
₹472
√(22.5 × EPS × book value per share)
ROIC
10.9%
vs 11.2% sector median
Cash flow to profit
1.17
CFO / PAT
Above 1.0 = operating cash flow exceeded reported profit
Margin change
−98
bps OPM YoY
Operating margin vs the same quarter last year
Sustainable growth
9.2%
ROE × earnings retention ratio
ROE stability
1.7
pp σ
Standard deviation of ROE across periods. Lower = more stable
Holder deltas
QoQ
pp
Prom +0.13FII −0.09DII −0.24
Latest quarter vs the previous one
Cash-accrual divergence
−1.4%
of assets
Low = accruals track cash flow
Strengths
+Price trades above its 200-day moving average (1.0x)
+Promoter holding rose by 0.3pp over the last year
+PE of 22.8x is below the sector median of 45.9x
Watch-outs
−Latest ROCE of 13% trails the sector median of 17%
−Borrowings are up 1154.4% since FY2016 (114 to 1430)

Peer comparison

Peers
NameP/EMar Cap ₹ CrROCE %ROE %

Quarterly results

Consolidated basis (as filed) · ₹ Cr · 13 quarters
As of 30 Jun 2026
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales1,4861,5951,6311,5171,5621,6481,6931,7701,7111,9101,8761,8482,150
Expenses1,2871,3871,3641,2571,3251,4091,4331,4981,4301,5941,5851,6201,818
Operating Profit199208266260237239260271281316292228332
OPM %13.4%13.0%16.3%17.1%15.2%14.5%15.4%15.3%16.4%16.5%15.6%12.3%15.4%
Other Income121034230101468−27215
Interest14161511131922252424232328
Depreciation66686969697170697476808998
Profit before tax130135185183157180178192190224162119222
Net Profit121137180178135153138157154184132202172
EPS (₹)6.146.959.189.076.857.807.047.987.859.406.7610.318.80

Profit & Loss

As of 30 Jun 2026
Consolidated · ₹ Cr · 12 years + TTM
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales2,0563,1663,1053,1313,9354,6065,3935,3065,6536,2296,6727,3457,784
Expenses1,6532,1592,4902,4883,0613,3833,9134,4324,9705,2965,6646,2246,617
Operating Profit4031,0076156438741,2231,4808746829321,0081,1211,167
OPM %19.6%31.8%19.8%20.5%22.2%26.6%27.4%16.5%12.1%15.0%15.1%15.3%15.0%
Other Income47279−398756−22856−14−1
Interest4553182716185056799498
Depreciation447283105115157183287275273279319342
Profit before tax3599365295417491,0001,368625355632707694726
Net Profit2837204034135838011,146521342616582671690
EPS (₹)15.0138.2021.3921.8931.0043.9758.3326.5017.4031.3329.6834.3335.27

Balance Sheet

As of 30 Jun 2026
Consolidated · ₹ Cr
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Jun 2026
Equity Capital383838383838393939393939—
Reserves8471,5601,8652,1822,6813,1825,0285,1984,3314,7795,1525,636—
Borrowings264114897081,1281,7475847177225131,2581,430—
Other Liabilities4937186981,0139311,0221,0581,1671,0901,1141,3251,658—
Total Liabilities1,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,763—
Fixed Assets5477087999931,1581,5521,7881,7982,3982,5472,5243,081—
CWIP83933961,0101,5511,8462,1832,304601524837683—
Investments287504249182361189693127141—
Other Assets1,0091,5411,4441,8962,0192,5732,5022,9023,0873,2814,2854,858—
Total Assets1,6412,4292,6893,9414,7785,9896,7097,1226,1836,4467,7738,763—

Cash Flows

As of 31 Mar 2026
Consolidated · ₹ Cr
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity1729483293128124491,46355272480388783
Cash from Investing Activity−256−307−486−884−756−731−840−372−448−321−568−506
Cash from Financing Activity87−224−12950359155−597−217−262−438444−164
Net Cash Flow3417−286−69115−12726−371445−37113

Ratios

As of 31 Mar 2026
12 periods
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %38.066.029.022.023.024.026.011.07.013.013.013.0
ROE %———————————13.4
EPS (₹)15.0138.2021.3921.8931.0043.9758.3326.5017.4031.3329.6834.33
Book Value (₹)———————————289.0
Face Value (₹)———————————2
P/E———————————22.8
Div Yield %———————————1.39
NPM %13.722.713.013.214.817.520.99.76.19.88.79.2
OPM %20.032.020.021.022.027.027.016.012.015.015.015.0
D/E0.300.070.050.320.410.540.120.140.170.110.240.25
P/B———————————3.0

Growth

As of 27 Sep 2026
Compounded sales growth
10 years+9.0%
5 years+6.0%
3 years+9.0%
TTM+14.0%
Compounded profit growth
10 years+0.0%
5 years−9.0%
3 years+28.0%
TTM+26.0%
Stock price CAGR
10 years+3.0%
5 years+2.0%
3 years+4.0%
Last year−5.0%
Return on equity
10 years16.0%
5 years11.0%
3 years13.0%
Last year13.0%

Shareholding pattern

As of 31 Mar 2026
Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters72.68%72.68%72.93%72.97%72.97%69.48%69.61%69.61%69.61%69.67%69.74%69.87%
FIIs10.61%10.61%9.16%9.50%8.29%6.56%6.02%4.55%4.46%3.94%4.26%4.17%
DIIs3.13%3.13%5.16%5.48%6.86%10.97%11.74%13.32%15.39%16.43%16.17%15.93%
Government————————————
Public13.58%13.58%12.75%12.05%11.88%12.99%12.63%12.53%10.54%9.96%9.83%10.00%
No. of shareholders50,61950,61946,85341,56447,28399,8091,06,43799,52276,56791,33686,43286,796
Change since Jun 2023 (pp)
Promoters −2.81FIIs −6.44DIIs +12.80Public −3.58

Documents

As of 27 Sep 2026
Announcements
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationUpdate On USFDA Inspection Conducted During 3Rd March, 2025 To 7Th March, 2025 At Bioequivalence Facility Located At Vadodara, Gujarat.Intimation Regarding Successful Completion Of Unannounced USFDA Onsite Bioequivalence Inspection.Intimation Under Regulation 30 Of SEBI LODR Regulations, 2015 - Incorporation Of A Wholly Owned Subsidiary CompanyAnnouncement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Annual reports
Annual Report 2026Annual Report 2025Annual Report 2024Annual Report 2023Annual Report 2022
Credit ratings
Rating updateRating updateRating updateRating updateRating update
Concalls
Aug 2026PPTAug 2026RecordingMay 2026TranscriptMay 2026PPTMay 2026RecordingFeb 2026TranscriptFeb 2026PPTFeb 2026PPTNov 2025TranscriptNov 2025PPTNov 2025Recording

Corporate actions

As of 29 Jul 2026
29 Jul 2026DIVIDENDDividend - Rs 12 Per Share—
29 Jul 2025DIVIDENDDividend - Rs 11 Per Share—
15 Jul 2024DIVIDENDDividend - Rs 11 Per Share—
28 Jul 2023DIVIDENDDividend - Rs 8 Per Share—
17 Aug 2022DIVIDENDInterim Dividend - Rs 10 Per Share—
19 Jul 2021DIVIDEND Annual General Meeting/Dividend - Rs 14 Per Share—
16 Mar 2020DIVIDEND Interim Dividend - Rs 7 Per Share Special Dividend - Rs 3 Per Share—
18 Jul 2019DIVIDEND Annual General Meeting/Dividend Rs 5.50/-—
18 Jul 2018DIVIDEND Annual General Meeting/Dividend- Rs 4 Per Share (Purpose Revised)—
11 Jul 2017DIVIDEND Annual General Meeting/Dividend -Rs 4/- Per Share—
20 Jul 2016DIVIDEND Annual General Meeting/Dividend - Rs 4/- Per Share—
22 Jul 2015DIVIDENDAnnual General Meeting/ Dividend - Rs 3.50/- Per Share—
17 Jul 2014DIVIDENDAnnual General Meeting / Dividend - Rs 3/- Per Share—
29 Jul 2013DIVIDENDAnnual General Meeting And Dividend Rs.2.50 Per Share—
31 Jul 2012DIVIDENDAnnual General Meeting / Dividend Rs 1.40 Per Share—
Fundamentals from a third-party compiler of exchange filings; prices from the exchanges. Not investment advice.© 2026 āagman